BPG is committed to discovery and dissemination of knowledge
Observational Study
Copyright: ©Author(s) 2026.
World J Hepatol. May 27, 2026; 18(5): 117441
Published online May 27, 2026. doi: 10.4254/wjh.v18.i5.117441
Table 3 Prevalence of metabolic dysfunction-associated steatotic liver disease among the three study groups, n (%)
Variable
Overt hypothyroidism (A) (n = 48)
Subclinical hypothyroidism (B) (n = 48)
Control (C) (n = 48)
P value
Paire-wise comparison
MASLD by ultrasound
Non-MASLD13 (27.1)21 (43.8)45 (93.8)< 0.001A vs B: 0.135
MASLD35 (72.9)27 (56.3)3 (6.3)A vs C: < 0.001
B vs C: < 0.001
MASLD by MRI
Non-MASLD14 (29.2)21 (43.8)45 (93.8)< 0.001A vs B: 0.203
MASLD34 (70.8)27 (56.3)3 (6.3)A vs C: < 0.001
B vs C: < 0.001


Write to the Help Desk